Kanāda - angļu - Health Canada

sandoz canada incorporated - pomalidomide - capsule - 3mg - pomalidomide 3mg

Kanāda - angļu - Health Canada

sandoz canada incorporated - pomalidomide - capsule - 4mg - pomalidomide 4mg

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

celgene limited, a bristol myers squibb company - pomalidomide 1mg;   - capsule - 1 mg - active: pomalidomide 1mg   excipient: gelatin indigo carmine iron oxide yellow mannitol pregelatinised maize starch sodium stearyl fumarate titanium dioxide - pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

celgene limited, a bristol myers squibb company - pomalidomide 2mg;   - capsule - 2 mg - active: pomalidomide 2mg   excipient: erythrosine gelatin indigo carmine iron oxide yellow mannitol pregelatinised maize starch sodium stearyl fumarate titanium dioxide - pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

celgene limited, a bristol myers squibb company - pomalidomide 3mg;   - capsule - 3 mg - active: pomalidomide 3mg   excipient: gelatin indigo carmine iron oxide yellow mannitol pregelatinised maize starch sodium stearyl fumarate titanium dioxide - pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

celgene limited, a bristol myers squibb company - pomalidomide 4mg;   - capsule - 4 mg - active: pomalidomide 4mg   excipient: brilliant blue fcf gelatin indigo carmine mannitol pregelatinised maize starch sodium stearyl fumarate titanium dioxide - pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - pomalidomide 1mg - capsule - 1 mg - active: pomalidomide 1mg excipient: gelatin iron oxide red iron oxide yellow maltodextrin microcrystalline cellulose sodium stearyl fumarate titanium dioxide - pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - pomalidomide 2mg - capsule - 2 mg - active: pomalidomide 2mg excipient: gelatin iron oxide red iron oxide yellow maltodextrin microcrystalline cellulose sodium stearyl fumarate titanium dioxide - pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - pomalidomide 3mg - capsule - 3 mg - active: pomalidomide 3mg excipient: gelatin indigo carmine iron oxide red iron oxide yellow maltodextrin microcrystalline cellulose sodium stearyl fumarate titanium dioxide - pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - pomalidomide 4mg - capsule - 4 mg - active: pomalidomide 4mg excipient: erythrosine gelatin indigo carmine iron oxide red iron oxide yellow maltodextrin microcrystalline cellulose sodium stearyl fumarate titanium dioxide - pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.